NCT02140762 - Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents | Biotech Hunter

Enrollment

305

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

February 28, 2015

Conditions

Meningococcal Disease

Interventions

BIOLOGICAL

MenABCWY

Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.

OTHER

Placebo

0.5 mL saline solution (IM)

BIOLOGICAL

MenACWY

Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.

Trial Locations (8)

Accelovance, Inc, Melbourne

Accelovance, Inc, Huntsville

Bluegrass Clinical Research, Inc., Louisville

Senders Pediatrics, Cleveland

Heartland Research Associates LLC, Newton

Heartland Research Associates, LLC, Wichita

Meridian Clinical Research, Omaha

The Children's Clinic of Jonesboro, P.A., Jonesboro